Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

Benzinga · 1d ago
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.